Methylprednisolone treatment in aplastic anaemia. 1986

S Issaragrisil, and A Piankijagum

Twenty patients with aplastic anaemia were treated with a short term bolus of methylprednisolone. Seven patients were refractory to anabolic steroids and were observed in very long follow-up periods of 14-104 months. Thirteen patients had never been treated. The latter group also received anabolic steroids. Five out of 20 patients responded to the treatment while the remaining patients did not or died. Responders among patients refractory to anabolic steroids had shorter duration of disease compared to non-responders. No recurrence of aplasia was observed in all responders.

UI MeSH Term Description Entries
D008297 Male Males
D008775 Methylprednisolone A PREDNISOLONE derivative with similar anti-inflammatory action. 6-Methylprednisolone,Medrol,Metipred,Urbason,6 Methylprednisolone
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

S Issaragrisil, and A Piankijagum
August 1991, British journal of haematology,
S Issaragrisil, and A Piankijagum
May 1992, British journal of haematology,
S Issaragrisil, and A Piankijagum
April 1991, American journal of hematology,
S Issaragrisil, and A Piankijagum
January 1989, Bailliere's clinical haematology,
S Issaragrisil, and A Piankijagum
June 1998, Lancet (London, England),
S Issaragrisil, and A Piankijagum
May 1965, Lancet (London, England),
S Issaragrisil, and A Piankijagum
April 1972, Lancet (London, England),
S Issaragrisil, and A Piankijagum
May 1965, Lancet (London, England),
S Issaragrisil, and A Piankijagum
October 1972, Acta medica Scandinavica,
Copied contents to your clipboard!